Mersana Therapeutics to Host Conference Call Announcing First Quarter 2019 Financial Results and Business Updates
May 02 2019 - 8:00AM
Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced that it will host
a conference call and webcast on Thursday, May 9, 2019 at 8:00 a.m.
ET to report financial results for the first quarter ended March
31, 2019 and provide business updates.
To access the call, please dial 877-303-9226 (domestic) or
409-981-0870 (international) and provide the Conference ID 1378664.
A live webcast of the presentation will be available on the
Investors & Media section of the Mersana website
at www.mersana.com.
About Mersana Therapeutics Mersana
Therapeutics is a clinical-stage biopharmaceutical company
using its differentiated and proprietary ADC platforms and its
modular Synthemer scaffold to develop highly targeted drugs with
increased tolerability and expanded opportunities to deliver
meaningful clinical benefit to cancer patients. Mersana’s lead
product candidate, XMT-1536, is in a Phase 1 clinical trial in
patients with tumors expressing NaPi2b, including ovarian cancer,
NSCLC adenocarcinoma, and other cancers. In addition, multiple
partners are using Mersana’s platform to advance their ADC
pipelines.
Contact:
Investor & Media Contact Sarah Carmody,
617-844-8577scarmody@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Apr 2023 to Apr 2024